Replies to post #684644 on NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Hankmanhub, This is my layman’s thinking on why DCVax can potentially use “non-self” cancer or viral antigens and still be substantially non-toxic.

DCVax-L process
- target (malignant epitopes from tumor lysate, antigen)
- dendritic cell (leukapheresis)
- education, maturation
- equals DCVax-L

DCVax-L as a best therapy
- both the target and drug/vaccine are from self
- 100% personalized, non-toxic, most efficacious
- Equals a 100% match between target and actual cancer

DCVax as a (potential vaccine) immunization against a set of cancer antigens
- The dendritic cell has to be from self. Otherwise the immune system would destroy it upon entry
- The target can be off-the-shelf (a bank of epitopes/antigens).
- The education and maturation of the DC with target epitopes has to be done outside of the body (DCVax manufacturing process).
- Once matured, DCVax should not create an immune reaction. Why? Because these “non-self” epitopes would being carried by the DC. They get a free pass. After all, that is the job of DCs, to carry "non-self" and malignant epitopes to the lymph nodes for presentation and to activate an immune response.
- That process would then result in unique memory T cells and B cells becoming activated, one for each of the malignant epitopes, ie the immunization against a set of cancer antigens.

I would also refer to Doclee’s post here.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174000850